Skip to main content
SpringerLink
Log in

IMiDs induce pleiotropic anti-cancer effects

  • Short Review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Lenalidomide (Revlimid®, also known as CC-5013) and pomalidomide (CC-4047) are IMiDs and chemical derivatives of thalidomide. Lenalidomide was introduced in 2004 and is currently approved for treatment of multiple myeloma and 5q-myelodysplastic syndromes (MDS). In addition, IMiDs are currently tested in a wide variety of haematological as well as solid tumours. IMiDs have three main anti-tumour properties, i.e. a direct anti-tumour effect, an inhibitory/modulatory effect on the tumour stroma/microenvironment supporting growth and survival of tumour cells including anti-angiogenic properties as well as a very potent immunomodulatory effect. The latter includes activation of T, NK and NKT cells as well as modulation of the function of mononuclear cells (DC and monocytes). However, the exact anti-cancer mechanisms of IMiDs in vivo remain elusive so far. This brief review will focus on the current concepts explaining the anti-cancer effects of IMiDs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med, 357(21): 2123–2132, 2007

    Article  PubMed  CAS  Google Scholar 

  • List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355(14): 1456–1465, 2006

    Article  PubMed  CAS  Google Scholar 

  • Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res, 67(2): 746–755, 2007

    Article  PubMed  CAS  Google Scholar 

  • LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood, 103(5): 1787–1790, 2004

    Article  PubMed  CAS  Google Scholar 

  • Haslett PA, Hanekom WA, Muller G, Kaplan G. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis, 187(6): 946–955, 2003

    Article  PubMed  CAS  Google Scholar 

  • Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest, 118(7): 2427–2437, 2008

    PubMed  CAS  Google Scholar 

  • Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother, 2008

  • Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood, 108(2): 618–621, 2006

    Article  PubMed  CAS  Google Scholar 

  • Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood, 112(13): 5180–5189, 2008

    Article  PubMed  CAS  Google Scholar 

  • Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol, 163(1): 380–386, 1999

    PubMed  CAS  Google Scholar 

  • Payvandi F, Wu L, Haley M, Schafer PH, Zhang LH, Chen RS, et al. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol, 230(2): 81–88, 2004

    Article  PubMed  CAS  Google Scholar 

  • Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res, 2008

  • Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature, 451(7176): 335–339, 2008

    Article  PubMed  CAS  Google Scholar 

  • Pellagatti A, Jadersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients. Proc Natl Acad Sci USA, 104(27): 11406–11411, 2007

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tyrolean Cancer Research Center, Internal Medicine V (Haematology and Oncology) and Laboratory of Tumorimmunology, Medical University Innsbruck, Innsbruck, Austria

    Dominik Wolf

Authors
  1. Dominik Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dominik Wolf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wolf, D. IMiDs induce pleiotropic anti-cancer effects. memo 2 (Suppl 1), 10–12 (2009). https://doi.org/10.1007/s12254-009-0097-7

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-009-0097-7

Keywords

Search

Navigation